Annovis Bio: Funding, Investors & Team (Nov 2026)
Annovis Bio is a pharmaceutical company focused on creating new therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. They are working on two drugs: Posiphen®, which aims to treat early stages of AD and PD to potentially slow the disease progression, and BNC, which targets late-stage AD to potentially stabilize cognitive decline.
Annovis Bio has raised $58.1M across 5 funding rounds on record, the most recent an undisclosed round of $15.0M announced in May 2026.
That round is above the $8.9M median round size for Biotechnology companies tracked on FundedIQ over the last two years.
Annovis Bio Company Profile and Key Stats
Latest funding round on record: May 2026.
Annovis Bio Funding Rounds
Annovis Bio raised $8.7M in an undisclosed round announced in Apr 2023.
1.8 years later, an undisclosed round of $21.0M was announced in Feb 2025.
8 months later, an undisclosed round of $3.4M was announced in Oct 2025.
6 months later, an undisclosed round of $10.0M was announced in Apr 2026.
1 month later, an undisclosed round of $15.0M was announced in May 2026.
Annovis Bio Founders and Leadership Team
Contact details for the Annovis Bio team: 1 of 2 have an email address on file.
Start 14-day free trial →Annovis Bio Funding Compared to Other Biotechnology Startups
Annovis Bio's latest round of $15.0M is above the median round in Biotechnology. Medians cover the last 24 months of disclosed rounds.
Funded Startups Like Annovis Bio in Biotechnology and Berwyn
Companies Similar to Annovis Bio
Araceli Biosciences specializes in creating scientific instruments for discovering tissue- and cell-based…
Switchpoint Bio is a biotechnology company that offers immune relevant drug treatments.
Nanopath Inc. is a company that specializes in molecular diagnostics and allows for fast, high-quality…
Frontier Bio is creating lab-grown human tissues as an ethical replacement for animal studies and is setting…
Delix Therapeutics is a neuroscience company focused on harnessing the power of psychoplastogens—novel…
Rgenta Therapeutics develops a pipeline of oral, small-molecule RNA-targeting medicines with an initial focus…
Zafrens, a pharmaceutical research organization, focuses on designing life sciences solutions for…
Quanta is a biotechnology company uncovering novel cancer therapeutic candidates to target driver oncogenes.…
Arctic Therapeutics specializes in finding the genetic origins of common diseases and creating successful…
100XBIO is creating a cutting-edge platform for analyzing multiple T-cells automatically, aiming to…
MEND is a company focused on life sciences, determined to assist individuals in achieving better health…
Prolific Machines is a biotech company located in San Francisco, California, that was established in 2020. It…
Annovis Bio Funding FAQs
What does Annovis Bio do?
Annovis Bio is a pharmaceutical company focused on creating new therapies for Alzheimer's disease, Parkinson's disease, and other neurodegenerative conditions. They are working on two drugs: Posiphen®, which aims to treat early stages of AD and PD to potentially slow the disease progression, and BNC, which targets late-stage AD to potentially stabilize cognitive decline.
How much funding has Annovis Bio raised?
Annovis Bio has raised $58.1M across 5 rounds on record. The most recent is an undisclosed round of $15.0M announced in May 2026.
When did Annovis Bio last raise funding?
Annovis Bio's most recent funding round on record is an undisclosed round of $15.0M, announced in May 2026.
Who founded Annovis Bio?
FundedIQ lists Maria L (Founder), Maria Maccecchini (Founder) at Annovis Bio.
Where is Annovis Bio headquartered?
Annovis Bio is based in Berwyn, Pennsylvania, United States.
How many employees does Annovis Bio have?
Annovis Bio is in the 1-10 employee band.
How does Annovis Bio's funding compare to other Biotechnology startups?
Annovis Bio's latest round of $15.0M is above the $8.9M median round size for Biotechnology companies on FundedIQ across 4,188 tracked companies over the last two years.
About FundedIQ's Annovis Bio Funding Data
FundedIQ tracks announced funding rounds and refreshes this profile every week. Round dates, stages and amounts are normalised to a single format, converted to US dollars, and de-duplicated: two records of the same round announced days apart are merged, and two genuinely different rounds are kept apart on the amounts they disclose. Amounts shown are the disclosed figures only — a round announced without a number is listed and excluded from the total rather than estimated.
Employee counts are reported bands, not exact headcounts. Founder and executive names carry the job title on record. Anything we do not hold for Annovis Bio is left off this page rather than filled in.
Know who just raised. Then know who to reach.
Startup funding intelligence on every funded startup: the round, the investors and the founders, as a file in your inbox or searchable in the app.
Radar from $49/mo · Pro from $149/mo. Card required, nothing charged until day 15, and we email you 3 days before that. Need something specific? Custom plans from $499/mo.